Q-omics provides the consensus-scored HDAC11 profile across patient tissues and cancer cell-line models. HDAC11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HDAC11 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HDAC11 protein abundance shows 19,466 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where HDAC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDAC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDAC11 survival associations across molecular data types. HDAC11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDAC11 RNA expression–survival associations across cancer types. High HDAC11 expression shows unfavorable associations in LIHC and LAML, but favorable associations in UVM, KIRP, KIRC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HDAC11 RNA expression.
This table summarizes HDAC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HDAC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDAC11 shows lower tumor expression in KIRC, THCA, LUSC and LUAD and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher HDAC11 RNA expression in normal versus tumor tissue (log2 FC = −1.149, t-test p < 0.001).
This table shows molecular features associated with HDAC11 in patient tissues and cancer cell lines. In patient samples, HDAC11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HDAC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
